Bioengineering at the University of Strathclyde, have collected a substantial body of work based on a novel approach to transdermal transport of molecules with a direct application in minimally-invasive diagnostics. One key parameter of interest is potassium due to its importance as an indicator of cardiac status. This project has developed relationships with a commercial partner with an appropriate background in network and manufacturing to take this technology from T2 stage to T3 where commercial application is possible. The technical aim of the programme would be to first modify the existing potassium monitoring patch to take full advantage of the strengths of both parties. The second generation manufactured patch would then be assessed in vitro and within a healthy volunteer test group. In a future development, if suitable, the patch would be assessed for the potential incorporation into the partners Heartcheck monitor. This would be assessed in terms of technical feasibility and the potential for the patch to perform within the given FDA requirements for Allowable Total Error (ATE). To begin the translational process from T2 to T3 and develop the test patch, the research fellow would be contracted full time for 12 months to work between the parties for the development and assessment of the transdermal potassium technology.
|Effective start/end date||1/12/11 → 30/09/12|